ISIC welcomes EFSA draft opinion on safety of caffeine

Print this page

The European Food Safety Authority (EFSA) today published a draft Scientific Opinion on the safety of caffeine. ISIC welcomes this opinion, which supports our own position on the science behind coffee, caffeine and health.

EFSA’s provisional findings state that “single doses of caffeine up to 200mg and daily intakes of up to 400mg do not raise safety concerns for adults in Europe”. Other provisional findings include:

  • Single doses of caffeine up to 200mg are considered safe for adults (18-65 years) also when consumed less than two hours before intense exercise.
  • For pregnant women, caffeine intakes of up to 200mg a day are considered safe for the foetus.
  • Single doses of caffeine up to 200 mg and daily intakes of up to 400mg consumed by lactating women in the general population are considered safe for the breastfed infant.
  • For children (3-10 years) and adolescents (10-18 years), daily intakes of 3mg per kg of body weight are considered safe.
  • Single doses of 100mg may increase sleep latency (the amount of time it takes to fall asleep) and shorten sleeping time in some adults, particularly when consumed close to bedtime.

EFSA is also planning to hold a stakeholder meeting in the first week of March 2015 to explain and discuss the draft opinion with interested parties. Details of the meeting will be announced shortly on EFSA’s website. We are currently reviewing the EFSA draft opinion in detail with our science experts.

Coffee, caffeine and health

Coffee is enjoyed by millions of people around the world and its components have been extensively researched. Taken overall, the research indicates that caffeinated coffee consumed in moderation (typically 3-5 cups per day) has positive effects on both mental performance and physical endurance performance. The body of scientific research also suggests that moderate lifelong coffee consumption may reduce the risk of neurodegenerative conditions (such as age-related cognitive decline, Alzheimer’s Disease and Parkinson’s Disease), type 2 diabetes and a range of liver diseases (such as liver fibrosis, cirrhosis, fatty liver disease and Hepatitis-C).

For more information on coffee, caffeine and health, click here.

This information is intended for Healthcare professional audiences.
Please consider the environment before printing.